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Abstract
Purpose:  To investigate the outcome of HIV-seropositive patients under highly active
antiretroviral treatment (HAART) with anal cancer treated with radiotherapy (RT) alone or in
combination with standard chemotherapy (CT).
Patients and methods: Clinical outcome of 81 HIV-seronegative patients (1988 – 2003) and 10
consecutive HIV-seropositive patients under HAART (1997 – 2003) that were treated with 3-D
conformal RT of 59.4 Gy and standard 5-fluorouracil and mitomycin-C were retrospectively
analysed. 10 TNM-stage and age matched HIV-seronegative patients (1992 – 2003) were compared
with the 10 HIV-seropositive patients. Pattern of care, local disease control (LC), overall survival
(OS), cancer-specific survival (CSS), and toxicity were assessed.
Results: RT with or without CT resulted in complete response in 100 % of HIV-seropositive
patients. LC was impaired compared to matched HIV-seronegative patients after a median follow-
up of 44 months (p = 0.03). OS at 5 years was 70 % in HIV-seropositive patients receiving HAART
and 69 % in the matched controls. Colostomy-free survival was 70 % (HIV+) and 100 % (matched
HIV-) and 78 % (all HIV-). No HIV-seropositive patient received an interstitial brachytherapy boost
compared to 42 % of all HIV-seronegative patients and adherence to chemotherapy seemed to be
difficult in HIV-seropositive patients. Acute hematological toxicity reaching 50 % was high in HIV-
seropositive patients receiving MMC compared with 0 % in matched HIV-seronegative patients (p
= 0.05) or 12 % in all HIV-seronegative patients. The rate of long-term side effects was low in HIV-
seropositive patients.
Conclusion: Despite high response rates to organ preserving treatment with RT with or without
CT, local tumor failure seems to be high in HIV-positive patients receiving HAART. HIV-
seropositive patients are subject to treatment bias, being less likely treated with interstitial
brachytherapy boost probably due to HIV-infection, and they are at risk to receive less
chemotherapy.
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Background
The incidence of cancer of the anal canal is rising due to
the increasing prevalence of HIV-infection and HPV-infec-
tion [1-4]. Standard therapy for invasive anal cancer is
radiotherapy (RT) or chemo-radiation resulting in local
tumor control (LC) rates and disease-free survival (DFS)
in HIV-seronegative patients approaching 72 % and 73 %,
respectively [5-7]. Few data exist on treatment outcome in
HIV-seropositive individuals. Retrospective survival anal-
yses of cohort patients in the pre-HAART era indicate that
HIV-infection is associated with poorer outcome after
combined chemo-radiation [7-10]. Though, some investi-
gators reported lower doses of RT and chemotherapy
being applied in patients with HIV-infection [3,11]. Side-
effects tended to be more frequent and more intense in
HIV-seropositive patients without HAART than in HIV-
seronegative patients in some reports [12-14] whereas in
others acute toxicity was moderate [15]. The increased
likelihood of therapy-related toxicity correlated with low
CD4 count in HIV-seropositive patients in the pre-HAART
era in one report [16].
The introduction of HAART resulted in an increase of CD4
counts in responders and prolongation of survival. The
influence of HAART on concomitant cancer treatment-
related toxicity and treatment outcome of anal cancer
remains controversial. Analysing very small patient
cohorts, some authors showed no changes of the overall
survival (OS) rates of anal cancer since the introduction of
HAART [1] while others reported favorable treatment and
toxicity outcome compared with results of the non-HIV
population [17,18].
The aim of this study was to investigate clinical character-
istics of HIV-seropositive and HIV-seronegative patients
and whether the outcome in respect of treatment toxicity
and survival after standard curative 3-D conformal RT
with or without chemotherapy (CT) of invasive cancer of
the anal canal is comparable between HIV-seropositive
patients receiving HAART and stage and age matched HIV-
seronegative patients.
Patients and methods
Patients
Ninety-one patients presenting with histologically proven
invasive carcinoma of the anal canal between 1988 and
2003 at the Department of Radiation Oncology, Zurich,
were treated with curative 3-D conformal RT alone or
combined with CT. First, clinical characteristics, pattern of
care and outcome of 81 HIV-seronegative patients were
retrospectively analysed. Then, 10 consecutive HIV-serop-
ositive patients receiving HAART (1997 and 2003) were
retrospectively compared to 10 HIV-seronegative patients
(1992 – 2003) matching for TNM-stage and age. Selection
of matched HIV-negative patients was as follows: of 81
HIV-seronegative patients with invasive carcinoma of the
anal canal, 42 patients matched for TNM-stage and of
these 42 patients 10 patients corresponded for age and
grading. After obtaining informed consent and internal
institutional review approval, clinical outcome was ana-
lyzed by reviewing medical records and interviews of
patients.
Pre-treatment staging was performed in all patients and
included digital examination, endoluminal ultrasound,
chest x-rays and either an abdominal ultrasound or CT
scanning. Patients were staged according to the system
adopted by the American Joint Committee on Cancer [19]
and the Union International Contre le Cancer (UICC)
before the primary treatment [19]. Post-treatment evalua-
tion included a clinical examination including digital pal-
pation at each visit and regular anal ultrasounds.
Anoscopy and post-treatment biopsies were only per-
formed when a suspicious lesion was identified.
Treatment
No patient in the HIV-seropositive had primary radical
surgery with colostomy compared with 5 HIV-seronega-
tive patients (6 %). All patients except one HIV-negative
patient that died during treatment completed curative 3-D
conformal RT. Standard RT was administered over a five-
week period to a dose of 45 Gy in 1.8 Gy per fraction fol-
lowed either directly by an external beam radiotherapy
(EBRT) boost or an interstitial high-dose rate (192Ir-HDR)
boost after an interval of 2 – 3 weeks to deliver a total dose
of 59.4 Gy. The fractionated HDR brachytherapy boost
(14 Gy/7 fractions, thrice daily) was applied to patients
with T1 – T3 tumors appropriate for interstitial treatment
after EBRT of 45 Gy.
Chemotherapy consisted of fluorouracil (5-FU) and mito-
mycin-C (MMC). 5-FU was applied as a continuous infu-
sion during the first five days of radiotherapy at a dose of
750 mg/m2 or over four days at 1000 mg/m2. The cycle
was repeated during week five of RT. MMC was given as an
i.v. bolus on day one of radiotherapy (15 mg/m2) or twice
during week 1 and 5 (10 mg/m2). When contraindicated,
MMC was replaced by cisplatin given i.v., during 1 hour
infusion, in week 1 and 5. Criteria for "non-adherence to
chemotherapy" included omittance of chemotherapy or
dose-reduction because of side effects.
Toxicity
The common terminology criteria for adverse events v3.0
was used for assessing acute and late treatment toxicity
[20]. Follow-up records addressing long-term toxicity
were available for 95 % of the patients. Sphincter function
was assessed by digital palpation.Radiation Oncology 2006, 1:29 http://www.ro-journal.com/content/1/1/29
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Statistics
Mean values are indicated with standard deviation. Differ-
ences between groups on continuous variables were tested
using the Mann- Whitney test. SPSS version 12 was used
with exact p-values. Fisher's exact test was used to test for
differences between groups on categorical variables. Sur-
vival was calculated from the beginning of RT to the day
of death or the date of last follow-up and time-to- recur-
rence from beginning of RT to the day of recurrence or
date of last follow-up. Survival curves for the two groups
were plotted according to the Kaplan-Meier method. Dif-
ferences in survival across the groups were tested using the
Log rank (Mantel-Cox) test.
Results
Results of HIV-seronegative patients
Mean age of the 81 HIV-seronegative patients was 61.6 +/
- 12.7 years and 75 % of the patients were female (Table
1). Sixty-one patients (74 %) had a very good perform-
ance status (WHO 0°). Nine patients (11 %) had grad 1
and 3 patients (4 %) grade 2 WHO performance status
and for 7 patients it was not known. At time of diagnosis,
tumor stage distribution for T1/T2/T3/T4 was 15 %, 43 %,
31 % and 11 %. The majority of patients presented with
nodal negative disease (61 %) and low grad tumors, i.e.
G1 and G2 (62 %). Radical surgery with up-front colos-
tomy was performed in 6 % of the patients. All of them
received postoperative RT or chemo-radiation. RT-dose
was 57.2 +/- 5 Gy and RT-duration was 53.6 +/- 17 days.
Interstitial 192Ir-HDR brachytherapy boost was appropri-
ate in 42 %. CT was applied to 72 % and included MMC
in 64 % of all patients. After a median follow-up of 45
months OS at 10 years was 48 % and CSS was 75 %. Local
failure rate at 10 years was 13 %. Eleven patients received
salvage surgery resulting in a 10-year colostomy-free rate
of 84 % (78 % if the 5 patients with primary radical sur-
gery are included). Two of them had not achieved com-
plete response to chemo-radiation. Severe acute side
effects were relatively rare with 31 %. The most frequent
severe side effects were dermatitis (17 %), diarrhea (6 %)
or thrombopenia (12 %). Two patients died during or
immediately after treatment due to cerebral bleeding
under thrombopenia or cardiac failure. Chronic side
effects could be evaluated in 54 patients (67 %). Thirteen
patients (24 %) experienced either ulcera (2 %), chronic
proctitis (11 %) or sphincter pressure impairment (15 %).
Results of HIV-seropositive patients receiving HAART and 
matched-pair analysis
Patient's characteristics
Mean age of HIV-seropositive patients was low with 44.5
+/- 10 years and most of them were male gender (90 %)
(Table 3). All 10 HIV-seropositive patients were in good
health. In patients with HIV-infection, median and mean
CD4 counts were 266/μl and 303/μl (+/-241/μl), respec-
tively (Table 2). HIV-seropositive patients presented with
early stage (80 % T1/2), nodal negative (90 %) and well
differentiated (80 % G1/2) tumors as shown in Table 3.
Pattern of treatment
No HIV-seropositive patient received radical surgery with
up-front colostomy. Also in the matched HIV-seronega-
tive cohort no patient underwent primary surgery. Total
RT dose did not differ between HIV-seropositive and
matched HIV-seronegative patients (57 – 58 Gy) whereas
the duration of RT was longer in the matched HIV-seron-
egative cohort compared with the matched HIV-negative
cohort (47.4 +/- 6 d vs. 59.8 +/- 10 d; p = 0.007). This was
due to the interval between the EBRT and the brachyther-
apy boost used in HIV-seronegative patients. A significant
difference was observed in the application of HDR-brach-
ytherapy. No HIV-seropositive patient received HDR-
brachytherapy boost compared with 60 % of the matched
HIV-seronegative patients (p  = 0.005). Adherence to
chemotherapy seemed to be more difficult in HIV-serop-
ositive patients with HAART than in the stage- and age-
matched HIV-seronegative patients (30 % vs. 80 %,
respectively; p = 0.08). Lack of adherence was either due to
non-compliance, co-morbidity or concomitant medica-
Table 1: Clinical characteristics, pattern of care and outcome of 
HIV-seronegative patients (n = 81). MMC = mitomycin-C, RT = 
radiotherapy, OS = overall survival, CSS = cancer-specific 
survival, m = months.
Variable HIV-seronegative patients
gender m:f = 20:61 (24.7%)
age 61.6 +/- 12.7 y
WHO performance status I° 14.8 %
T1/T2/T3/T4 14.8 %/43.2 %/30.9 %/11.1 %
N0/N1/N2/N3 60.5 %/17.3 %/11.1 %/8.6 %
G 1/G 2/G 3 8.6 %/53.1 %/27.2 %
sphincter invasion 25 (30.9 %)
histology (basaloid) 25 (30.9 %)
radical surgery 5 (6 %)
chemotherapy 58 (71.6 %)
MMC 52 (64.2 %)
RT-dose 57.2 +/- 5 Gy
RT-duration 53.6 +/- 17.3 d
brachytherapy 34 (41.9 %)
follow-up (median/mean) 45 m/51 +/- 34 m
OS at 10 years 48 %
CSS at 10 years 75.1 %
acute side effects (3°) 25 (30.9 %)
skin 14 (17.3 %)
diarrhea 5 (6.2 %)
hematological (% of MMC patients) 6 (11.5 %)
infection 3 (3.7 %)
other 1 (1.2 %)
chronic side effects (n = 54) 13 (24 %)
ulcera 1 (1.9 %)
proctitis 6 (11.1 %)
sphincter pressure impairment 8 (14.8 %)Radiation Oncology 2006, 1:29 http://www.ro-journal.com/content/1/1/29
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tion, low CD4 counts, or severe thrombocytopenia before
or during treatment.
Response and survival
Median follow-up was 44 months in the matched groups
(HIV+: 8 – 76 months; HIV-: 19 – 116 months). Treat-
ment with RT alone or combined with CT achieved com-
plete remission in 100 % in HIV-seronegative as well as
matched HIV-seropositive patients. Three HIV-seroposi-
tive patients with HAART suffered from local failure com-
pared with no patient in the age-matched HIV-
seronegative cohort, resulting in a statistically worse time-
to-local recurrence (p  = 0.03, Figure 3). Fifty-seven
months after treatment, one HIV-seropositive patient suf-
fered from a local relapse while no HIV-seronegative
patient experienced local failure after 4 years. Colostomy-
free survival was below 70 % (HIV+) and 100 % (matched
HIV-). A non-significant trend towards impaired time-to-
recurrence for HIV-seropositive patients was observed (4
recurrences in HIV-positive patients versus 1 recurrence in
HIV-negative patients; p  = 0.1). In HIV-seropositive
patients, local recurrences were histologically confirmed
Table 2: Clinical characteristics of HIV-seropositive patients with access to HAART (n = 10). TNM: TNM classification of malignant 
tumors, HAART: Highly active anti-retroviral treatment. * indicates: HAART was started with or immediately before RT. CDC: HIV 
disease stage (Centers for Disease Control). RT: Radiotherapy. HDR: High-dose-rate brachytherapy. CT: Chemotherapy. 5-FU: 
Fluorouracil. MMC: Mitomycin-C. f/u: Follow-up. APR: Abdomino-perineal resection. NED: No evidence of disease. MD: Moist 
desquamation. TC-penia: Thrombocytopenia. 1 = stavudin, 2 = didanosin, 3 = lamivudin, 4 = zidovudin, 5 = efavirenz, 6 = abacavir, 7 = 
ritonavir, 8 = nelfinavir, 9 = amprenavir.
TNM CDC CD4 HAART RT (Gy) RT 
duration 
(days)
CT (mg) 5-
FU/MMC
acute 
toxicity
chronic side 
effects
recurrence f/u
T1N0M0 C3 80 1, 2, 7 54 45 16100 incontinence 
I°
local APR, 
recurrence
T3N0M0 C3 847 1, 3 59.4 45 13600/34 MD none NED
T1N0M0 C3 64 2, 3, 6, 9 59.4 48 15400/15 MD, Tc-penia skin III° none NED
T3N0M0 A3 88 3, 4, 5 59.4 47 14400/30 incontinence 
I°
none NED
T2N0M0 A1 591 1, 2, 7 54 60 11250/40 loco-regional palliation, 
failed
T2N0M0 B3 354 1, 2, 8 * 59.4 37 none MD none NED
T2N2M0 C3 105 3, 4, 8 * 59.4 47 none none NED
T2N0M0 C3 262 1, 3, 8 59.4 56 6800/20 Tc-penia inguinal failed
T2N0M0 C3 190 3, 4, 6 55.8 43 none local APR, NED
T2N0M0 A2 370 3, 4, 5 55.5 46 15520/19 Tc-penia none NED
Table 3: Patient's characteristics of matched HIV-seropositive patients and HIV-seronegative patients matched for TNM-stage and age 
(n = 10 vs. 10).
Variable Study group Fisher's exact test
HAART-HIV + HIV -
gender m:f = 9:1 (90%) m:f = 1:9 (10%) 0.001
age (mean) 44.5 +/- 10 y 45.2 +/- 7 y NS
WHO-perform. Status I° 2 (20 %) 0 NS
T1 2 2 NS
T2 6 6 NS
T3 2 2 NS
N0 9 9 NS
N2 1 1 NS
G1 2 NS
G2 6 8 NS
G3 2N S
Sphincter invasion 2 (22 %) 3 (30 %) NS
Histology (basaloid) 2 (20 %) 4 (40 %) NS
Mitomycin C 6 (60 %) 8 (80 %) NS
Brachytherapy 0 (0 %) 6 (60 %) 0.005
RT-dose (mean) 57.7 +/- 2.4 Gy 58.5 +/- 3 Gy NSRadiation Oncology 2006, 1:29 http://www.ro-journal.com/content/1/1/29
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in two cases. The two remaining patients suffered from
locally extensive tumor disease (N = 1) or additional liver
metastasis (N = 1). However, no significant difference in
overall and cancer-specific survival was observed (Figure 1
and 2). The 1-year OS in the matched HIV-seropositive
and -seronegative cohort was 90 % and 100 %, and the 5-
year OS was 70 % and 69 %, respectively. The cause of
death in young non-HIV individuals was predominantly
secondary cancer. Two HIV-infected patients receiving
HAART died of anal cancer compared to none of the HIV-
negative control patients. In the present study, no HIV-
seropositive patient with HAART died as a result of HIV-
associated infections.
Acute toxicity
Although the frequency of acute grade 3/4 toxicities was
doubled in HIV-seropositive individuals compared with
matched HIV-seronegative patients (60 % vs. 30 %), this
did not reach statistical significance because of low
patient number. Therefore, a worse outcome in respect of
acute toxicity can not be excluded. There was no grade 5
toxicity in the HIV-positive group or the matched HIV-
negative group.
Cutaneous and gastrointestinal toxicity: Acute skin toxic-
ity grade 3 was seen in 3 HIV-positive patients with
HAART resulting in a rate of 30 % compared with 20 % of
matched HIV-seronegative patients (p = NS). In the HIV-
seropositive patients, no severe diarrhea was observed
while it was reported in one HIV-seronegative patient.
Hematological toxicity: Three of six (50 %) HIV-seroposi-
tive patients receiving HAART who were treated with
chemotherapy with MMC developed acute thrombocyto-
penia grade 3 (Table 1), compared to 0% of 8 matched
HIV-negative patients. This resulted in a significant higher
severe hematological toxicity rate (p = 0.05). Notably, two
of the patients had CD4 count above 200 cells/μl.
Late toxicity
In respect of chronic side effects including chronic skin
ulceration grade 3, complaints from chronic proctitis,
Time-to-local recurrence of HIV-seropositive patients with  access to HAART (n = 10) (thin line) and T-/N-stage, age- matched HIV-seronegative patients (n = 10) (thick line) with  anal cancer (p = 0.03) Figure 3
Time-to-local recurrence of HIV-seropositive patients with 
access to HAART (n = 10) (thin line) and T-/N-stage, age-
matched HIV-seronegative patients (n = 10) (thick line) with 
anal cancer (p = 0.03).
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Overall survival of HIV-seropositive patients with access to  HAART (n = 10) (thin line) and T-/N-stage, age-matched  HIV-seronegative patients (n = 10) (thick line) with anal can- cer (p = NS) Figure 1
Overall survival of HIV-seropositive patients with access to 
HAART (n = 10) (thin line) and T-/N-stage, age-matched 
HIV-seronegative patients (n = 10) (thick line) with anal can-
cer (p = NS).
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Cancer-specific survival of HIV-seropositive patients with  access to HAART (n = 10) (thin line) and T-/N-stage, age- matched HIV-seronegative patients (n = 10) (thick line) with  anal cancer (p = NS) Figure 2
Cancer-specific survival of HIV-seropositive patients with 
access to HAART (n = 10) (thin line) and T-/N-stage, age-
matched HIV-seronegative patients (n = 10) (thick line) with 
anal cancer (p = NS).
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sphincter muscle dysfunction and incontinence grade 1
no significant difference was found between HIV-seropos-
itive and matched HIV-seronegative patients. Prolonged
wound healing was seen in only 1 patient with HIV-infec-
tion (10%) without evidence of tumor persistence com-
pared with no patient in the matched HIV-seronegative
cohort. Though, this patient developed a secondary lym-
phoma at the site of ulceration which was treated with
chemotherapy. One patient of each group developed
sphincter pressure impairment after treatment. The rate of
sphincter function preservation was around 70 % (HIV+)
and 100 % (matched HIV-). One HIV-seropositive patient
under HAART died 2.5 years after RT because of sigmoid
colon perforation, an area outside the RT treatment fields.
Discussion
HIV-infected individuals are confronted with a an
increased risk for cancer disease, including anal carcinoma
[1-4]. Although HAART has favorably influenced the inci-
dence of non-Hodgkin lymphoma and Kaposis' sarcoma
[21,22], the incidence of anal cancer has remained ele-
vated in HIV-positive individuals [17,23-29]. HAART has
a profound influence on a broad variety of organs and
physiological systems resulting in improved function of
the immune system, especially the CD4 T-cell compart-
ment, and prolongs survival [30-40]. Protease inhibitors
and non-nucleoside reverse transcriptase inhibitors are
interfering with CT, because they are substrates and potent
inhibitors or inducers of the cytochrome P450 (CYP) sys-
tem [41]. Protease inhibitors may potentially act as radio-
as well as chemosensitizers [42,43] putatively resulting in
either better tumor control or increased toxicity.
This study is the first matched-pair analysis on anal cancer
patients with HIV-infection receiving HAART comparing
outcome with HIV-seronegative controls accounting for
the three most important prognostic-factors T-stage, N-
stage and age [44-46]. Several findings are of clinical
importance. (i) Standard 3-D conformal RT alone or com-
bined with standard CT can achieve complete tumor
response rates of 100% in patients with HIV-infection
under HAART. (ii) Despite the good response rates and
maintained treatment with HAART, local failure rate is
significantly higher when compared with the prognosti-
cally similar tumor-stage and age matched control cohort
possibly compromising colostomy-free and cancer-spe-
cific survival. (iii) Nevertheless, disease-free and overall
survival is similar in HIV-positive patients under HAART
compared with HIV-negative patients. (iv) Standard
chemo-radiation with mitomycin-C is associated with a
high rate of severe acute hematological toxicity but not
with increased long-term side effects in HIV-seropositive
patients with HAART. (v) HDR-brachytherapy was
applied less frequently to HIV-seropositive patients and
adherence to chemotherapy was more difficult.
Since the introduction of HAART, one comparative [18]
and six non-comparative retrospective reports have evalu-
ated the outcome of HIV-seropositive patients with access
to HAART [1,17,47-50]. Though, only 4 of these studies
included more than 8 patients [1,17,18,50]. The study by
Kinsella et al., presented at the Annual Meeting of the
American Society for Therapeutic Radiology and Oncol-
ogy (ASTRO) 2005, also compared consecutive HIV-sero-
positive patients receiving HAART with consecutive HIV-
seronegative patients and concluded that standard com-
bined chemo-radiation with 5-FU and MMC or cisplatin
can achieve good tumor response (86 %) and DFS (79 %)
in HIV-seropositive patients under antiretroviral therapy,
similar to the HIV-negative cohort [18]. Tumor response
was 100 % in our study and DFS at 5 years (70 %) com-
pares similar to the results of Kinsella et al.. In contrast to
the study by Kinsella et al., we observed an increased local
recurrence rate in HIV-seropositive patients resulting in a
colostomy rate of 30 %. Colostomy rate was not reported
by Kinsella et al. The follow-up of our study was consider-
ably longer with 44 months compared with 28 months in
their study. It seems that a long follow-up time may be
important in HIV-seropositive patients since in our study
1 HIV-seropositive patient had a local failure after 57
months which was not observed in the 81 HIV-seronega-
tive patients. Importantly, HIV-seronegative patients in
our study were TNM- as well as age- matched while in the
study by Kinsella et al. the HIV-seronegative cohort
included more advanced tumor stages (III and IV). Addi-
tionally, HIV-seronegative patients were an average of 17
years older than HIV-positive patients which may repre-
sent a different prognostic cohort. In respect of toxicity,
they observed a low hematological severe toxicity rate in
HIV-positive patients which is different to our study. This
may be explained in part by the use of cisplatin instead of
MMC. If so, cisplatin might be an advantageous alterna-
tive to MMC if applied at standard dose and not at high-
dose like in the study by Blazy et al. [50]. Another study by
Allen-Mersh  et al. reported treatment and toxicity out-
come after chemo-radiation in 46 HIV-seropositive
patients with sufficient response to HAART [17]. After a
median follow-up of 35 months, 1-year OS (85 %) was
comparable to our results (90 %). In line with our study
and not the study by Kinsella et al., they also noticed a
high recurrence rate of 34 % after 1 year. In our analysis,
local failure rate was 20 % (1 year) and 30 % (4 years).
Due to toxicity, 22 % of the HIV-positive patients required
RT breaks or altered chemotherapeutic regimens and 78 %
of the patients experienced grade I-III toxicity. 70 % of
patients were reported to receive MMC. In our study 60 %
experienced acute grade III/IV toxicities and 50 % of the
patients receiving MMC had severe thrombocytopenia
requiring dose reduction. The importance of the CD4
count to toxicity of chemo-radiation was emphasized by
Hoffman et al. who compared patients of the pre-HAARTRadiation Oncology 2006, 1:29 http://www.ro-journal.com/content/1/1/29
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era in respect of CD4 count and found an increased rate of
acute side effects associated with low CD4 counts [16].
The CD4 counts in the cohort of Allen-Mersh et al. may
have been higher than the CD4 counts of the patients in
the present trial. Notably, in the present study, two of the
three patients with severe thrombocytopenia had a CD4
count above 200 cells/μl. Due to the small number of
patients in the present study, no conclusions regarding
CD4 counts are made. It is debatable, whether HAART
contributed to the elevated acute toxicity. Some reports
suggested a sensitizing effect of protease inhibitors on
chemotherapy [42] or radiotherapy [43].
Results from randomized trials compare similar to ours
regarding tumor response (100%), tumor progression at 1
year (20 %) and OS (70 % at 5 years). In the study by Bar-
telink  et al. corresponding values were approximately
94%, 17 % and 56 % [51]. 4-year OS was 74 % in the trial
by Flam et al. [6]. While colostomy-free survival reported
was around 70 – 72 % in the whole patient cohort [6,51],
in nodal negative and T1/2 tumors colostomy-free rate
was 87 % and above 90 %, respectively [6]. Since our
study included 80 % T1/2 and 90 % nodal negative
tumors in HIV-seropositive patients, local tumor control
rate and colostomy-free survival of below 70 % in HIV-
seropositive individuals seem to be relatively poor and
would be expected higher.
Thus, despite good tumor response and similar OS in our
study, our data support the clinical experience that young
HIV-seropositive patients with HAART and good perform-
ance status are prone to worse treatment outcome, a find-
ing supported by Allen-Mersh et al. or the data of Blazy et
al. who showed that high-dose RT (60 – 70 Gy) combined
with 5-FU and cisplatin – given at a different regimen,
though – resulted in grade 3 neutropenia in 4 of 9 HIV-
seropositive patients receiving HAART (44%) [50]. Also,
Bower et al. reported on 26 HIV-infected patients in the
pre- and post-HAART era (16 patients with HAART) that
the actuarial 2-year overall survival did not change after
introduction of HAART [1].
There must be factors others than age or tumor stage for
the higher local recurrence since the patients were well
matched in respect of these prognostic factors. Such fac-
tors may be either patient-related or treatment-related.
Patient-related factors may be persisting immunological
alterations even after controlling HIV replication with
HAART. Treatment-related factors may be the difficulties
to apply full dose chemotherapy [52]. Chemotherapy and
MMC in particular, was applied less frequently and with
worse adherence in the HIV-seropositive patients either
due to non-compliance, co-morbidity or concomitant
medication, low CD4 counts, or severe thrombocytopenia
before or during treatment. The importance of additional
chemotherapy for the local tumor control has been dem-
onstrated in several randomized trials [6,51,53-55]. Thus,
we assume that chemotherapy is important for the local
treatment success in HIV-positive patients, as well.
Another difference of treatment between seropositive and
seronegative patients was the use of brachytherapy that
was more reluctantly applied in HIV-seropositive patients.
The stringent matching procedure for TNM-stage, age and
grade to some extent did not allow an additional match-
ing for brachytherapy. Though, retrospective analysis of
81 HIV-seronegative patients at our Department revealed
no better outcome for patients receiving a HDR brachy-
therapy boost compared to patients with an EBRT boost.
Due to missing randomized trials or retrospective com-
parative studies indicative for a definitive clinical benefit
of brachytherapy, we lack evidence to encourage the use of
interstitial treatment in HIV-seropositive patients with
anal cancer [56-59]. In the present cohort, it is not clear
whether brachytherapy has been used more reluctantly
because of the HIV-infection harbouring a risk of compli-
cations and treatment-related death or because of other
reasons, such as the particular anatomical presentation of
the disease.
There are some limitations to the present study. Because
of the low incidence only a small number of patients
could be analysed with limited statistical power. There-
fore, only clear and important differences were found.
Due to the limited number of cases, this study must be
considered hypothesis-generating and not conclusive. The
case-control analysis improves the validity of the study
results although there may still be a selection bias and
despite that the controls were derived through a stringent
selection algorithm, which did not allow changing match-
ing cases before analysis. Furthermore, when the HIV-
seropositive patients were compared with all, non-
matched consecutive 81 HIV-seronegative patients, time-
to-local recurrence was still inferior in HIV-seropositive
patients under HAART. Matching for T-/N- stage as well as
age is important since both are significant statistical
parameters and because the demographics of HIV-
patients with anal cancer differ from those of HIV-seron-
egative patients a fact not considered in the study by Kin-
sella et al.. Grading is not an independent risk factor when
adjusted for stage [60] and gender can not generally be
considered as a prognostic factor, although some multi-
variate analyses suggest that women may have a better
prognosis than men [51,61-63]. The performance status
was similar in all the patients investigated in this study,
never below 80% of Karnofsky scale [46].
We conclude that HIV-seropositive patients with HAART
and a good performance status are likely to achieve a com-
plete response with standard 3-D conformal RT alone orRadiation Oncology 2006, 1:29 http://www.ro-journal.com/content/1/1/29
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combined with standard chemotherapy, although the risk
for local relapse is high. Nevertheless, overall survival is
comparable to HIV-seronegative patients. Despite good
performance status the tolerability of chemo-radiation
with mitomycin-C is limited by the toxicity of full dose
chemotherapy. Therefore, in HIV-seropositive anal cancer
patients with access to HAART, combined chemo-radia-
tion is challenged to be more efficient at reduced toxicity
at which cisplatin may represent a feasible option.
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